Moderna’s $2.8 Billion Loss Contrasts With Vertex’s $4 Billion Profit
Moderna’s 2025 revenue fell about 39.2% as demand for COVID-19 products shifted toward seasonal cycles, while the company reported a net loss of nearly $2.8…
Moderna stock faces a sharp contrast with Vertex Pharmaceuticals: Moderna reported nearly $1.9 billion in revenue and a net loss of approximately $2.8 billion for FY 2025, while Vertex recorded close to $12.1 billion in revenue and nearly $4.0 billion in net income. The figures underscore the different financial profiles investors must weigh when comparing the biotechnology companies.
Moderna’s revenue declined roughly 39.2% from the prior year as demand for COVID-19 products tapered and the market shifted toward seasonal cycles. Vertex, focused on medicines for serious diseases, reported revenue growth of approximately 9.6% year over year.
The gap is stark.
The comparison, reported by Yahoo Finance, centers on Moderna’s effort to expand its mRNA technology across diseases and Vertex’s established position in cystic fibrosis treatments. The companies operate in biotechnology but carry different business risks and levels of profitability.
Moderna weighs pipeline ambitions against losses
Moderna sells mRNA-based medicines, primarily infectious disease vaccines including Spikevax and mNEXSPIKE for COVID-19. It maintains a global manufacturing footprint and works with partners on drug development, including Merck on oncology candidates. The company also recently partnered with Recordati to advance new therapeutics.
Those efforts sit alongside pressure on its finances. Moderna reported a net margin of negative 145.2% for FY 2025 and negative free cash flow of nearly $2.1 billion. Its current ratio was approximately 3.3x on its December 2025 balance sheet, while its debt-to-equity ratio was roughly 0.2x.
The company also faces competition from Pfizer, Sanofi and GSK in the vaccine market. Legal exposure is another risk: the source reports a $950 million settlement with Arbutus Biopharma in March 2026 over intellectual property. Moderna also reported a net loss of $1.34 billion in Q1 2026.
For investors, the figures show why the Moderna case depends on whether its products and development partnerships can support a business whose COVID-19 sales have declined. The source presents expansion of mRNA medicines as the company’s ambition, but its reported losses and negative free cash flow underline the financial challenge.
Vertex posts profit, with concentration risks
Vertex reported close to $12.1 billion in FY 2025 revenue and nearly $4.0 billion in net income, producing a net margin of roughly 32.7%. It generated close to $3.2 billion in free cash flow during the fiscal year.
Its December 2025 balance sheet showed a current ratio of approximately 2.9x and a debt-to-equity ratio of roughly 0.2x. The company focuses on medicines for serious diseases and holds a dominant position in the cystic fibrosis market, according to the source.
That concentration is also a vulnerability. Vertex depends heavily on its cystic fibrosis portfolio and faces clinical development risks. The source cites the discontinuation of its VX-264 diabetes program, complex manufacturing for gene therapies such as CASGEVY, and patent litigation involving CRISPR technology.
Vertex also collaborates with CRISPR Therapeutics, Zai Lab and Entrada Therapeutics on clinical programs. Its profitable results distinguish it from Moderna’s reported losses, but the comparison does not remove the risks tied to either company’s business and development plans.
Yahoo Finance’s report says the choice between the two depends on an investor’s appetite for volatility. It also begins to characterize Vertex as significantly cheaper, but the available source text ends before giving the supporting valuation details.
Source: finance.yahoo.com
